Free Trial
→ The DOJ Just Paved the Way for Account Seizures (From Priority Gold) (Ad)
OTCMKTS:NWBO

Northwest Biotherapeutics 3/5/2024 Earnings Report

Northwest Biotherapeutics logo
$0.26 -0.01 (-3.56%)
As of 06/20/2025 03:59 PM Eastern
ProfileEarnings History

Northwest Biotherapeutics EPS Results

Actual EPS
-$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Northwest Biotherapeutics Revenue Results

Actual Revenue
$0.45 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Northwest Biotherapeutics Announcement Details

Quarter
Date
3/5/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Northwest Biotherapeutics' next earnings date is estimated for Thursday, August 7, 2025, based on past reporting schedules.

Conference Call Resources

Northwest Biotherapeutics Earnings Headlines

Northwest Biotherapeutics, Inc.: Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments
June 13, 2025 | finanznachrichten.de
Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments
June 11, 2025 | prnewswire.com
The IRS Loophole That Lets You Own Gold Tax-Free
What if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? No gimmicks. No shady tricks. Just a powerful IRS-approved loophole that most Americans have never heard of. It's called a Self-Directed Gold IRA, and it's quietly becoming the go-to wealth protection strategy for people who see the writing on the wall. When you take the next step, you could qualify for up to $10,000 in FREE GOLD & SILVER with your purchase of a qualified account.
June 21, 2025 | Advantage Gold (Ad)
Northwest Biotherapeutics: A Spike On Their Expected Imminent Approval
April 22, 2025 | seekingalpha.com
Investors Watching Two Small-Caps for News on Potential Major Advancements in Cancer Treatments
January 13, 2025 | msn.com
Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing
December 26, 2024 | prnewswire.com
See More Northwest Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Northwest Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Northwest Biotherapeutics and other key companies, straight to your email.

About Northwest Biotherapeutics

Northwest Biotherapeutics (OTCMKTS:NWBO), a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

View Northwest Biotherapeutics Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles